Gynae-Oncology Trials

A list of our early phase gynae-oncology trials which are open to recruitment at University College London Hospitals.

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

Additional early phase clinical trials recruiting Gynae-Oncology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.

CRAIN A phase 1b TiTE-CRM dose escalation clinical trial of tolinapant in combination with standard radical chemoradiotherapy in cervical cancer
IRAS Number:	1004372
Principal Investigator:	Dr Asma Sarwar
Drug Class/Treatment:	Tolinapant (ASTX660) - non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Combination with standard radical chemoradiotherapy
Patient Population:	Cervical Cancer
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

MOV18-02 (EPS101-10-02) EPS101-10-02: A Phase 1b Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer
IRAS Number:	1009485
Principal Investigator:	Dr Rowan Miller
Drug Class/Treatment:	Mov18 IgE (IgE Antibody)
Patient Population:	Advanced Ovarian Cancer Advanced epithelial ovarian, fallopian tube cancer, or primary peritoneal cancer with histologically- high-grade serous or endometrioid features or a predominantly serous/ endometrioid component.
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)